DBVT News and Press, DBV Technologies S.A. From 09/21/22

Montrouge, France, September 21, 2022 DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it recei...

Summary Two new Breakout Stocks for Week 38 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +116.8% YTD. This week two picks beat 10% gains in less than week with peak gains in BKKT +14.5% and CXM +12.5% with RIOT peaking ...

Montrouge, France, September 7, 2022 DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the M odified Viaskin Peanut P atch in Peanut - Allergic Children Ages 4 to 7 Years DBV has finalized t...

Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of Directors Names Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceu...

DBV Technologies press release ( NASDAQ: DBVT ): Q2 GAAP EPS of -$0.35 misses by $0.03 . Revenue of $1.53M beats by $0.29M . Shares +3.19% AH. For further details see: DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by...

Montrouge, France, August 1, 2022 DBV Technologies Reports Second Quarter 2022 Financial Results DBV closes Q2 with a cash balance of $248M following recent ATM and PIPE offerings DBV continues to practice budget discipline measures; cash used in operating ...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...

DBV Technologies is a French company traded on Nasdaq which is developing treatments for food allergies. Their technology is a patch that delivers a very small daily dose of the allergen to desensitize the patient. The company previously received a CRL due to issues with the adhes...

Kohl's ( KSS ) -19% after ending strategic review, warning on soft Q2 sales ; on terminating deal talks with Franchise Group . Borr Drilling ( BORR ) -15% gets more time from lenders on refinancing talks . Revelation Biosciences ( REVB ) -12% ...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...